EWTX · Edgewise Therapeutics

The thesis

Edgewise Therapeutics is modestly more likely than not to beat the S&P 500 over the next three months. The case rests on FDA-cleared Phase 3 plans for its heart drug EDG-7500, $1.74 billion of cash and unconfirmed takeover reports. The start of the STRATUS-HCM Phase 3 trial, which the company guides to the fourth quarter of 2026, settles whether execution holds. The drug's real value depends on placebo-controlled results, and the company has published no readout date.

On 6 November 2026, traders circulated an unconfirmed Betaville alert saying two European drugmakers and one U.S.-listed company had been involved in a sale process over the prior two months, according to Seeking Alpha. GuruFocus reported on 7 November 2026, citing unnamed sources, that Edgewise had retained advisers. Neither report carries a company comment.

The shares closed at $38.87 on 5 November 2026, the session of the FDA news, and at $48.74 on 9 November 2026. They closed at $45.82 on 12 November 2026, so most of the takeover-report gain is still in the price.

Bullish and bearish views on Edgewise Therapeutics, Inc.

The bull case on Edgewise Therapeutics, Inc. (EWTX), in brief: takeover interest has been reported. The bear case: the sale report is unconfirmed.

Bull case

• Takeover interest has been reported. Seeking Alpha reported on 6 November 2026 that a Betaville alert named two European pharmaceutical companies and one U.S.-listed company as involved in a sale process. GuruFocus put the market value at $4.93 billion on 7 November 2026. Seeking Alpha via TradingView
• FDA feedback clears the Phase 3 plan. Edgewise said on 5 November 2026 that it submitted the STRATUS-HCM protocol after its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and that the start remains on track for the fourth quarter of 2026. Company release
• Dosing would not depend on echocardiograms. Patients move from 50 mg to 100 mg to 150 mg daily at four-week intervals, based on tolerance, per the 5 November 2026 release. Edgewise says European and Japanese regulators gave generally consistent feedback.
• The trial gives two separate chances. STRATUS-HCM enrolls about 600 adults with hypertrophic cardiomyopathy (HCM), about 200 with obstructive and 400 with nonobstructive disease, and evaluates each group separately, per the 5 November 2026 release.
• Reported cash is $1.74 billion. Edgewise held $1,743.9 million of cash and marketable securities at 30 September 2026, up from $530.1 million at 31 December 2025, per its third-quarter results. Another $153.9 million of sale consideration sits in escrow, per the 10-Q. Q3 10-Q
• One broker raised its target sharply. Raymond James raised its price target to $85 from $66 on 6 November 2026.

Bear case

• The sale report is unconfirmed. Betaville labels this kind of alert "uncooked", per Seeking Alpha on 6 November 2026, and GuruFocus cited only unnamed sources on 7 November 2026. Edgewise has not confirmed talks, and no bidder has been named.
• Efficacy against placebo remains unproven. CIRRUS-HCM, announced 16 June 2026, treated 53 patients for 12 weeks with no placebo group. STRATUS-HCM runs 24 weeks and uses a different primary endpoint, change in peak oxygen consumption.
• Shares sit near the average analyst target. Wedbush cut its target to $51 from $53 on 5 November 2026, and MarketBeat put the average analyst target at $51.25 that day. The 12 November 2026 close of $45.82 is below both.
• An executive sold shares into the rally. Chief Financial Officer Michael Nofi exercised options on 10,937 shares and sold 4,442 shares at $45.43 on 10 November 2026, per an SEC Form 4.
• Contingent Servier money is uncertain. Up to $1.1 billion of Servier payments depends on Becker and Duchenne approvals and a U.S. sales threshold. None of it has been received.

Price setup

The shares closed at $45.82 on 12 November 2026, down from $47.57 on 11 November 2026 and $48.74 on 9 November 2026. The 52-week intraday high is $48.78, set on 9 November 2026, and the last close is 6.1% below it. The 52-week closing low is $20.42 on 13 November 2025.

The 50-day moving average is $41.25 and the 200-day moving average is $36.92, both as of the 12 November 2026 close. The 3-month change is 3.7%, against a close of $44.17 on 14 August 2026.

The gap from the $38.87 close on 5 November 2026 to the $45.04 close on 6 November 2026 came from the takeover reports. If no deal follows, the 5 November 2026 close and the 50-day average mark where the shares traded on the FDA news alone.

Catalysts ahead

• ~31 December 2026 (est.): End of the guided window for the STRATUS-HCM Phase 3 start. A start inside the window confirms execution after the FDA meeting; no announcement by that date breaks this part of the case.

What would change the view

A daily close below $36, which would put the shares under the 200-day moving average and below the 5 November 2026 close of $38.87, erasing the gains since the FDA news and the takeover reports. A STRATUS-HCM start moved into 2027 or a regulatory hold on the trial would also break the case.

The risks this note tracks, each with what would confirm it:

• The reported sale process produces no deal and the takeover premium fades. Confirmed by: a company denial, or no definitive agreement in the weeks after the 6 November 2026 reports while the shares give back the gain made since the 5 November 2026 close of $38.87.
• The STRATUS-HCM start slips beyond the guided fourth quarter of 2026. Confirmed by: a company disclosure moving initiation into 2027, or no initiation announced by 31 December 2026.
• Open-label CIRRUS-HCM improvements do not carry over to a placebo-controlled test of peak oxygen consumption. Confirmed by: STRATUS-HCM missing its Week 24 primary endpoint in the obstructive or nonobstructive study.
• Dose escalation without echocardiograms draws a safety or regulatory objection. Confirmed by: an FDA request to change the submitted protocol, a clinical hold, or a reported safety signal in the trial.
• Contingent Servier payments never arrive. Confirmed by: Servier or Edgewise disclosing a failed Becker or Duchenne program, or Edgewise disclosing a loss of escrowed amounts.

What it trades with

The shares trade mainly on company-specific news. The two large moves in November came from a company release on 5 November 2026 and deal reports on 6 November 2026. Biotech takeover sentiment and peer readouts in cardiac myosin drugs for HCM are the main outside influences. The $1.74 billion of reported cash backs a large part of the market value, which can soften declines driven by the wider market.